ArticleBriefings in bioinformatics2017
The role of drug profiles as similarity metrics: applications to repurposing, adverse effects detection and drug-drug interactions.
Article in Briefings in bioinformatics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- The future of metronomic chemotherapy: experimental and computational approaches of drug repurposing.Pharmacological reports : PR · 2025Review
- Signature reversion of three disease-associated gene signatures prioritizes cancer drug repurposing candidates.FEBS open bio · 2024Article
- PRID: Prediction Model Using RWR for Interactions between Drugs.Pharmaceutics · 2023Article
- A comprehensive tool for tumor precision medicine with pharmaco-omics data analysis.Frontiers in pharmacology · 2023Article
- Considerations and challenges for sex-aware drug repurposing.Biology of sex differences · 2022Review
- Alternative strategies in cardiac preclinical research and new clinical trial formats.Cardiovascular research · 2022Review
- A machine learning framework for predicting drug-drug interactions.Scientific reports · 2021Article
- Predicting Drug-Disease Association Based on Ensemble Strategy.Frontiers in genetics · 2021Article
- Drug Research Meets Network Science: Where Are We?Journal of medicinal chemistry · 2020Article
- From single drug targets to synergistic network pharmacology in ischemic stroke.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- A Novel Approach for Drug-Target Interactions Prediction Based on Multimodal Deep Autoencoder.Frontiers in pharmacology · 2019Article
- Proximal Pathway Enrichment Analysis for Targeting Comorbid Diseases via Network Endopharmacology.Pharmaceuticals (Basel, Switzerland) · 2018Article
- A two-tiered unsupervised clustering approach for drug repositioning through heterogeneous data integration.BMC bioinformatics · 2018Article
- DDR: efficient computational method to predict drug-target interactions using graph mining and machine learning approaches.Bioinformatics (Oxford, England) · 2018Article
- Predicting potential drug-drug interactions on topological and semantic similarity features using statistical learning.PloS one · 2018Article
- Support for phosphoinositol 3 kinase and mTOR inhibitors as treatment for lupus using in-silico drug-repurposing analysis.Arthritis research & therapy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Explosion of the availability of big data sources along with the development in computational methods provides a useful framework to study drugs' actions, such as interactions with pharmacological targets and off-targets. Databases related to protein interactions, adverse effects and genomic profiles are available to be used for the construction of computational models. In this article, we focus on the description of biological profiles for drugs that can be used as a system to compare similarity and create methods to predict and analyze drugs' actions. We highlight profiles constructed with different biological data, such as target-protein interactions, gene expression measurements, adverse effects and disease profiles. We focus on the discovery of new targets or pathways for drugs already in the pharmaceutical market, also called drug repurposing, in the interaction with off-targets responsible for adverse reactions and in drug-drug interaction analysis. The current and future applications, strengths and challenges facing all these methods are also discussed. Biological profiles or signatures are an important source of data generation to deeply analyze biological actions with important implications in drug-related studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.